| 2017-05-18 07:05:40 | Syndax price target raised to $24 from $20 at CitiCiti analyst Joel Beatty raised his price target for Syndax Pharmaceuticals to $24 saying he's encouraged by the early response data reported yesterday afternoon for Entinostat plus Keytruda in melanoma. The data are compelling enough to increase the drug's probability of approval in melanoma to 30% from 20%, Beatty tells investors in a research note. He keeps a Buy rating on Syndax. | |
|---|---|---|
| ||
| , … |
| |
|---|---|---|
| ||
| | |
| | |
| |
| | |
| ||
| | |
| , |
| |
| , |
| |
| ||
| | |
| , … |
| |
| , |
| |
| |
| , … |
| |
|---|---|---|
| | |
| | |
| ||
| |
| | |
| , |
| |
| ||
| ||
|